Gordon Campbell | Parliament TV | Parliament Today | News Video | Crime | Employers | Housing | Immigration | Legal | Local Govt. | Maori | Welfare | Unions | Youth | Search


Glivec For All Chronic Myeloid Leukaemia Patients

Glivec Now Funded For All Chronic Myeloid Leukaemia Patients

Novartis New Zealand is pleased to announce that its drug Glivec® (imatinib) will be fully funded as a first line treatment for newly diagnosed chronic myeloid leukaemia (CML) patients from 1 March 2003.

Since December Glivec has been funded in New Zealand for the treatment of CML only after conventional treatment with interferon had failed and for patients in the more advanced stages of the disease, known as accelerated phase and blast crisis.

Mr Andrew Moore, managing director of Novartis New Zealand, said Pharmac's decision to now fund Glivec in the early, so-called "chronic" phase of the disease recognises the outstanding benefits of the drug when it is administered to patients as early as possible after diagnosis.

"This decision will undoubtedly improve the chances of newly diagnosed patients of beating this debilitating disease and leading normal, productive lives," he said. "We applaud Pharmac's support of patients with this disease."

Mr Moore said that the latest clinical results show that patients taking Glivec first-line are nine times more likely to achieve a complete cytogenic response (74%) than those treated with the previous standard therapy, a combination of interferon-alpha and the chemotherapy agent cytosine arabinoside (8%). A cytogenic response is when cancer cells disappear from the bone marrow where they are produced. Even in later stages of the disease Glivec is considerably more effective than interferon therapy.

Currently 94 people with CML are funded for Glivec in New Zealand. From 1 March it is estimated a further 50 patients who could benefit from first-line treatment with Glivec will be eligible for funding.

Glivec, a signal transduction inhibitor, is one of the first cancer drugs to be developed using rational drug design, based on an understanding of how some cancer cells work. It was also approved for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (GISTs) - a rare stomach cancer - in New Zealand in July and received funding for this indication in December.

About Novartis

Novartis AG is a world leader in pharmaceuticals and consumer health. In 2001, the Group's businesses achieved sales of CHF 32.0 billion (USD 19.1 billion) and a net income of CHF 7.0 billion (USD 4.2 billion). The Group invested approximately CHF 4.2 billion (USD 2.5 billion) in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ about 74, 000 people and operate in more than 140 countries around the world. For further information please consult http://www.novartis.com

© Scoop Media

Parliament Headlines | Politics Headlines | Regional Headlines


Sector Opposes Bill: Local Government Bill Timeframe Extended

The Minister of Local Government Peseta Sam Lotu-Iiga has asked the Select Committee to extend the report back date for the Local Government Act 2002 Amendment Bill (No 2). More>>


Breed Laws Don’t Work: Vets On New National Dog Control Plan

It is pleasing therefore to see Louise Upston Associate Minister for Local Government calling for a comprehensive solution... However, relying on breed specific laws to manage dog aggression will not work. More>>


Not Waiting On Select Committee: Green Party Releases Medically-Assisted Dying Policy

“Adults with a terminal illness should have the right to choose a medically assisted death,” Green Party health spokesperson Kevin Hague said. “The Green Party does not support extending assisted dying to people who aren't terminally ill because we can’t be confident that this won't further marginalise the lives of people with disabilities." More>>


General Election Review: Changes To Electoral Act Introduced

More effective systems in polling places and earlier counting of advanced votes are on their way through proposed changes to our electoral laws, Justice Minister Amy Adams says. More>>

Gordon Campbell: On Our Posturing At The UN

In New York, Key basically took an old May 2 Washington Post article written by Barack Obama, recycled it back to the Americans, and still scored headlines here at home… We’ve had a double serving of this kind of comfort food. More>>


Treaty Settlements: Bills Delayed As NZ First Pulls Support

Ngāruahine, Te Atiawa and Taranaki are reeling today as they learnt that the third and final readings of each Iwi’s Historical Treaty Settlement Bills scheduled for this Friday, have been put in jeopardy by the actions of NZ First. More>>


Gordon Campbell: On The Damage De-Regulation Is Doing To Fisheries And Education, Plus Kate Tempest

Our faith in the benign workings of the market – and of the light-handed regulation that goes with it – has had a body count. Back in 1992, the free market friendly Health Safety and Employment Act gutted the labour inspectorate and turned forestry, mining and other workplace sites into death traps, long before the Pike River disaster. More>>

Get More From Scoop



Search Scoop  
Powered by Vodafone
NZ independent news